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Although Canadian guidelines for the diagnosis
and management of asthma have been published
over the last 15 years,1–4there has been little focus
on issues relevant to asthma in the young child or
on prevention strategies for asthma. Since the last
update in 2001,4 important issues and new stud-
ies focusing on asthma in early life have high-
lighted the need to incorporate new information
into the asthma guidelines. Reports pertaining to
a number of issues published between 2000 and
June 2003 were reviewed initially by small expert
resource groups. The results of these reviews were
discussed by stakeholders during a 2-day con-
sensus meeting from June 27 to June 28, 2003. A
working group with a pediatric focus met under
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Background:Guidelines for the diagnosis and management of asthma have been published over the last
15 years; however, there has been little focus on issues relating to asthma in childhood. Since the last
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work For Asthma Care and the Canadian Thoracic Society.Data published through December 2004 were
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the auspices of the Canadian Network For Asthma
Care, and a group focusing on adult asthma met
under the auspices of the Canadian Thoracic Soci-
ety. On the first day, these groups met separately
to discuss specific issues related to pediatric and
adult asthma; on the second day, they met jointly
to discuss the dissemination and implementation
of the asthma guidelines. Data published up to
December 2004 pertaining to each of the issues
considered by the consensus working group were
reviewed by the individual expert resource groups,
which concurred that these data were insufficient
to modify any of the recommendations that follow.
This summary reports the recommendations
for the prevention, assessment, and management
of asthma in children and adults. A level of evi-
dence is assigned to each recommendation, based
on the strength of the supporting data (Table 1).5
Background documents supporting recommen-
dations for children are published in a supple-
ment to the Canadian Medical Association Jour-
nal. Background documents supporting
recommendations for adults are published in the
Canadian Respiratory Journal.6
Definition and General Management 
of Asthma
The definition of asthma is descriptive and has not
changed since the publication of the 1999 Cana-
dian Asthma Consensus Guidelines.3 Asthma is
characterized by paroxysmal or persistent symp-
toms such as dyspnea, chest tightness, wheezing,
sputum production, and cough associated with
variable airflow limitation and airway hyperre-
sponsiveness to endogenous or exogenous stim-
uli.3 Inflammation and its resultant effects on air-
way structure are considered the main mechanisms
leading to the development and persistence of
asthma.
Optimal management of asthma requires ade-
quate evaluation of the patient and the patient’s
environment. Asthma control should be assessed
with specific criteria (Table 2).3 Severity is more
difficult to assess and may be determined only after
asthma control is achieved. Asthma control should
be assessed at each visit.
If control is inadequate, the reason(s) for poor
control should be identified, and maintenance
therapy should be modified if needed (Figure 1).
Any new treatment should be considered a ther-
apeutic trial, and effectiveness should be reeval-
uated after 4 to 6 weeks.
Inhaled corticosteroids (ICSs) should be intro-
duced as initial maintenance treatment, even when
the patient reports having symptoms fewer than
three times per week. Leukotriene receptor antag-
onists (LTRAs) are an alternative for patients who
cannot or will not use ICSs. If control is inadequate
on low-dose ICSs, identify the reasons for poor
control, and if indicated, consider additional ther-
apy with LTRAs or long-acting b2-agonists.
Table 1  Levels of Evidence
Level I Evidence is based on randomized
controlled trials (or meta-analysis of
such trials) of adequate size to ensure a
low risk of incorporating false-positive
or false-negative results.
Level II Evidence is based on randomized
controlled trials that are too small to
provide level I evidence. They may
show either positive trends that are not
statistically significant or no trends and
are associated with a high risk of false-
negative results.
Level III Evidence is based on nonrandomized
controlled or cohort studies, case series,
case-control studies, or cross-sectional
studies.
Level IV Evidence is based on the opinion of
respected authorities or expert
committees as indicated in published
consensus conference proceedings or
guidelines.
Level V Evidence is based on the opinions of
those who have written and reviewed
the guidelines on the basis of
experience, knowledge of the relevant
literature, and discussion with peers.
Adapted from Steering Committee on Clinical Practice
Guidelines for the Care and Treatment of Breast Cancer: a
Canadian consensus document.526 Allergy, Asthma, and Clinical Immunology / Volume 2, Number 1, Spring 2006
If good control has been sustained, consider-
ation should be given to gradually reducing main-
tenance therapy, with regular reassessments to
ensure that control remains adequate. This will
allow the determination of the minimum therapy
needed to maintain acceptable asthma control.
Education about asthma is an essential com-
ponent of asthma care. Poor asthma control is not
usually due to a lack of efficacy of the medication
but is more often related to suboptimal use of
medication or to aggravating factors, comorbidi-
ties, poor inhaler technique, poor environmental
control, or a lack of continuity of care. Subopti-
mal use of asthma medication may be the result
of inappropriate physician recommendations, poor
adherence, or both, perhaps as a result of undue
fear of the adverse effects of therapy. In the face
of poor asthma control, it is crucial to identify and
address the cause (Table 3).
Diagnosis of Asthma
Recommendations regarding the diagnosis of
asthma and the assessment of asthma severity in
adults and older children have not changed from
previously published recommendations.3 How-
ever, the diagnosis of asthma in the preschool
child is a major focus of the current discussion.
Recommendations
1. Physicians must obtain an appropriate
patient and family history to assist them
in recognizing the heterogeneity of wheez-
ing phenotypes in preschool-aged children
(level III) (see Table 4).
2. In those children unresponsive to asthma
therapy, physicians must exclude other
pathology that may suggest an alternative
diagnosis (level IV).
Table 2  Asthma Control Criteria
Parameter Frequency or Value
Daytime symptoms < 4 days/week
Nighttime symptoms < 1 night/week
Physical activity Normal
Exacerbations Mild, infrequent
Absence from work or  None
school, due to asthma
Need for b2-agonist, prn < 4 doses/week*
FEV1 or PEF ≥ 90% of “personal best”
PEF diurnal variation† < 10–15%
Adapted from Boulet LP et al.3
FEV1 = forced expiratory volume in 1 second; PEF = peak
expiratory flow; prn = pro ne rata (as needed).
*Introduction of inhaled corticosteroids should be consid-
ered early, even for those who report asthma symptoms
fewer than three times per week and appear to have ade-
quate control, based on these criteria. One dose per day
may be used, to prevent exercise-induced symptoms.
†Calculated as the highest PEF minus the lowest, divided
by the highest PEF 3 100 for morning and night (deter-
mined over a 2-week period).
Figure 1  Continuum of asthma management. Inhaled
corticosteroids (ICSs) should be introduced as ini-
tial maintenance treatment, even with symptoms
experienced less than three times per week. Although
less effective than low-dose ICSs, leukotriene recep-
tor antagonists (LTRAs) are an alternative for patients
who cannot or will not use ICSs. If control is inad-
equate on low-dose ICSs, identify the reason 
(or reasons) for poor control, and if indicated,
consider additional therapy with long-acting b2-
agonists or LTRAs. Severe asthma may require addi-
tional treatment with systemic corticosteroids.
Asthma control and maintenance therapy must be reg-
ularly reassessed.2003 Canadian Asthma Consensus Guidelines Executive Summary — Becker et al 27
3. The presence of atopy should be defined
because it is a predictor of persistent
asthma (level III).
Reproduced with permission from the Canadian
Medical Association Journal.
Diagnostic Tools
In children less than 3 years of age, neither lung
function testing nor assessment of airway inflam-
mation is clinically helpful nor commonly avail-
able for the diagnosis of asthma.4,7–9Asthma diag-
nosis in children less than 6 years of age depends
on history and physical examination. Table 4 pro-
vides some criteria to help identify a child suffering
from asthma. The greater the number of criteria
met, the greater the likelihood of asthma.
Preschool Wheezing
Preschool wheezing can be classified as (1) tran-
sient early-onset wheezing (before the age of 3
years), which will often be outgrown; (2) persis-
tent early-onset wheezing (before the age of 3
years), which persists in school age; and (3) late-
onset wheezing (after the age of 3 years),which is
less likely to resolve. Among preschool children
with wheezing,50 to 60% outgrow the problem.10,11
Role of Atopy
Recurrent wheezing in nonatopic preschool chil-
dren is likely to resolve in childhood, but atopy is
a predictor of persistent asthma.12–14 A clinical
“index” may help predict which wheezing children
are likely to have persistent asthma15 (Table 5).
Physicians must obtain personal and family his-
tories of atopy and must look specifically for the
presence of atopic dermatitis during the physical
examination. The presence of atopy can be estab-
lished by skin-prick testing16 or by measurement
of specific immunoglobulin E (IgE) antibodies17,18
and is suggested by elevated peripheral total IgE
and blood eosinophils.18–20
Prevention Strategies
Recommendations
• Primary Prevention of Asthma
1. With conflicting data on early life expo-
sure to pets, no general recommendation
can be made with regard to avoiding pets
for primary prevention of allergy and
asthma (level III). However,families with
biparental atopy should avoid having cats
or dogs in the home (level II).
Table 3  Frequent Reasons 
for Poor Asthma Control
Insufficient patient education, particularly on what
asthma is and how to control it
Insufficient use of objective measurements of 
airflow obstruction (PEF, FEV1), leading to 
over- or underestimation of asthma control
Misunderstanding of the role and side effects 
of medications
Overuse of b2-agonists
Insufficient use of antiinflammatory agents,
including intermittent use, inadequate dose,
and lack of use
Inadequate assessment of patient adherence
Lack of continuity of care
Adapted from Boulet LP et al.4
FEV1 = forced expiratory volume in 1 second; PEF = peak
expiratory flow.
Table 4  Criteria Supporting a Diagnosis of
Asthma in Preschool Children*
Severe episode of wheezing or dyspnea
Wheezing or dyspnea after 1 year of age
Three or more episodes of wheezing
Chronic cough (especially exercise-induced 
or at night)
Clinical benefits from antiasthma medications
*An increased number of criteria increases the likelihood
of asthma.28 Allergy, Asthma, and Clinical Immunology / Volume 2, Number 1, Spring 2006
2. There are conflicting and insufficient data
for physicians to recommend for or against
breastfeeding specifically for the preven-
tion of asthma (level III). Due to its
numerous other benefits, breastfeeding
should be recommended.
• Secondary Prevention of Asthma
3. Health care professionals should continue
to recommend the avoidance of tobacco
smoke in the environment (level IV).
4. For patients sensitized to house dust mites,
physicians should encourage appropriate
environmental control (level V).
5. In infants and children who are atopic but
do not have asthma, data are insufficient
for physicians to recommend other spe-
cific preventive strategies (level II).
• Tertiary Prevention of Asthma
6. Allergens to which a person is sensitized
should be identified (level I), and a sys-
tematic program to eliminate, or at least
to substantially reduce allergen exposure
in sensitized people, should be undertaken
(level II).
Reproduced with permission from the Canadian
Medical Association Journal.
Primary Prevention
Primary prevention of asthma is defined as inter-
vention before the development of asthma or any
predisposing disease such as atopic dermatitis,
food allergy, or allergic rhinitis. We focused on two
specific areas of primary prevention: breastfeed-
ing and exposure to pets in early life. Recom-
mendations relating to avoiding exposure to envi-
ronmental tobacco smoke remain unchanged.
Sensitization to allergens is one of the strongest
determinants of the subsequent development of
asthma. Several recent studies have suggested the
possibility that a cat or dog in the home early in a
person’s life might decreasethe risk of developing
allergy or asthma.21–27 Currently available data do
not provide conclusive guidance on exposure to
pets in early life. There is evidence that children with
biparental atopy and children whose mothers have
asthma should avoid exposure to pets in early life.26
There is clear evidence that breastfeeding pro-
tects against early wheezing syndromes.28,29How-
ever, recent studies suggest that breastfeeding
may increase the risk of persistent asthma.30,31
The reasons for this are speculative but may relate
to a lower incidence of infectious diseases among
breastfed children (the “hygiene hypothesis”) or
a higher rate of breastfeeding in atopic families
(confounding by indication). However, other ben-
efits of breastfeeding are sufficiently clear to rec-
ommend exclusive breastfeeding of infants for
the first 4 months of life or longer.
Secondary Prevention
Secondary prevention is defined as intervention in
infants and children who are at high risk for the
development of asthma but who have not yet devel-
oped asthma symptoms or signs.32 These patients
usually have allergic conditions and a family his-
tory of allergic disease.32There is currently insuf-
ficient evidence on pharmacologic treatment,con-
trol of environmental factors,and allergen-specific
immunotherapy to allow firm recommendations to
be made. Health care personnel should continue to
recommend the avoidance of smoke for all children
and the reduction of dust mites in the environment
of sensitized people.
Table 5  Predictors of Persistent Asthma in
Children Older than 6 Years
Stringent index*
Wheezing on three or more occasions during the 
first 3 years of life
One or more major risk factors† or two or more 
minor risk factors‡
Loose index*
Any wheezing during the first 3 years of life
One or more major risk factors† or two or more 
minor risk factors‡
Adapted from Rhodes HL et al.14
*Both listed conditions are necessary.
†Major risk factors are a parental history of asthma and
eczema in the child.
‡Minor risk factors are eosinophilia, wheezing without a
cold, and allergic rhinitis.
 2003 Canadian Asthma Consensus Guidelines Executive Summary — Becker et al 29
Tertiary Prevention
Tertiary prevention implies identifying allergens
to which persons are sensitized and undertaking
a systematic program to eliminate (or at least sub-
stantially reduce) allergen exposure in sensitized
people. This strategy is still endorsed.
Pharmacotherapy
Recommendations
• First-line maintenance therapy in children
1. Physicians should recommend inhaled cor-
ticosteroids (ICSs) as the best option for
antiinflammatory monotherapy for child-
hood asthma (level I).
2. There is insufficient evidence to recom-
mend leukotriene receptor antagonists as
first-line monotherapy for childhood
asthma (level I). For children who cannot
or will not use ICSs, leukotriene receptor
antagonists represent an alternative to ICSs
(level II).
• Intermittent treatment with ICS in children
3. There are insufficient data for physicians
to recommend a short course of high-dose
ICS in children with mild intermittent
asthma symptoms, and its safety has not
been established (level II).
4. Physicians must carefully monitor chil-
dren with intermittent symptoms to ensure
they do not develop chronic symptoms
requiring maintenance therapy (level IV).
5. Physicians should recommend that chil-
dren with frequent symptoms and/or severe
asthma exacerbations receive regular, not
intermittent,treatment with ICSs (level IV).
• Add-on therapy to ICSs
6. Long-acting b2-agonists are not recom-
mended as maintenance monotherapy in
asthma (level I).
7. If after reassessment of compliance, con-
trol of environment, and diagnosis, patients
are not optimally controlled with moder-
ate doses of ICSs, physicians may conduct
a therapeutic trial of leukotriene receptor
antagonist or long-acting b2-agonist as
add-on therapy for any individual child
(level IV).
Reproduced with permission from the Canadian
Medical Association Journal.
Relief Therapy
Short-acting b2-agonists have been used for symp-
tom relief for many years.33 Recently, a long-act-
ing but also fast-acting agent,formoterol,has been
approved for symptom relief.34 Fast-acting bron-
chodilators may be used to relieve acute intermit-
tent asthma symptoms. They should be used only
on demand, at the minimum dose and frequency
required. Need for a reliever more than three times
per week (aside from a preexercise dose) suggests
suboptimal asthma control and indicates the need
to reassess treatment. Inhaled ipratropium bro-
mide is less effective; but in the emergency room,
ipratropium bromide combined with short/fast-
acting b2-agonists is effective for the treatment of
severe acute asthma in children and adults.35,36
First-Line Maintenance Therapy
Early Inhaled Corticosteroid Treatment
The role of ICSs for early treatment of mild to mod-
erate asthma has been extensively evaluated. As
reported by a systematic review, treatment with
beclomethasone significantly improved forced
expiratory volume in 1 second (FEV1) and morn-
ing peak expiratory flow (PEF), reduced the use
of b-agonists, and reduced exacerbations, com-
pared with placebo.37In a recent large prospective
study of pediatric and adult patients with mild
asthma, the early use of moderate-dose inhaled
budesonide was associated with better control of
symptoms, improved FEV1, and, important, a
marked reduction in asthma exacerbations, com-
pared to placebo.3830 Allergy, Asthma, and Clinical Immunology / Volume 2, Number 1, Spring 2006
In children, ICS therapy may be associated
with mild reductions in linear growth,39 which
appear to occur primarily during the first year of
therapy. Prospective studies show that children
treated with moderate doses of an ICS for long peri-
ods attain their predicted adult height.40 There is
no evidence to support initial treatment with com-
bination therapy (an ICS and a long-acting 
b-agonist) for patients who were not previously
in a trial of an ICS alone.41
An alternative to using an ICS is using an
LTRA. Three well-designed trials,one in preschool
children and two in school-aged children,demon-
strated the superiority of an LTRA to placebo for
persistent asthma.42–44Montelukast was associated
with fewer days of asthma symptoms and b2-
agonist use, less use of rescue oral steroids, and (in
older children) greater improvement in lung function.
A Cochrane review of low-dose ICSs com-
pared with LTRA monotherapy in school-aged
children with mild to moderate airway obstruction
reported less use of b2-agonist in the ICS group
but no significant difference in symptoms, spiro-
metric measurements, or risk of asthma exacer-
bation requiring systemic steroids.45 There are
currently too few trials from which to draw any
firm conclusions. A recent systematic review com-
paring an ICS (400 mg of beclomethasone or
equivalent) to LTRAs for mild to moderate asthma
examined the results of 13 trials (all adult trials,
with one exception). This review found that adults
treated with LTRAs were more likely to suffer an
asthma exacerbation requiring a course of oral
prednisone.46Thus, ICSs remain the preferred ini-
tial treatment for asthma in children and adults.
Intermittent Treatment
Intermittent asthma symptoms are a common pat-
tern of asthma in infants and children; exacerba-
tions are usually triggered by viral infections of
the upper respiratory tract. This form of asthma is
less likely associated with atopy and may have a
different natural history. Treatment is problematic
because an optimal therapy has not been clearly
determined. Because such children are asympto-
matic between exacerbations, intermittent treat-
ment with an ICS is attractive to both physicians
and families, and this management strategy is
prevalent in Canada even though evidence to sup-
port this practice is scant.
Studies of preschool children treated with
high-dose intermittent therapy (beclomethasone
[2,250 mg per day] or budesonide [1,600–3,200 mg
per day]) for 5 to 10 days showed small reductions
in asthma symptom scores and a trend toward
less use of oral steroids; however, the duration of
symptoms and the number of emergency visits and
admissions to hospital did not appear to be affected
by this therapy.47–50Few studies have evaluated the
safety of intermittent high-dose ICS treatment.51
Inhaled Glucocorticoids with Added Therapy
For patients whose asthma is not adequately con-
trolled by ICS treatment, available therapeutic
options include (1) increased doses of an ICS and
(2) add-on therapy with a long-acting b2-agonist,
an LTRA, or theophylline.
Long-Acting b2-Agonists and
Leukotriene ReceptorAntagonists
Long-acting b2-agonists are safe and effective
medications for improving asthma control in older
children and adults whose asthma is not optimally
controlled despite regular maintenance therapy
with ICSs,41,52,53 but they should not be used as
monotherapy.54
Among children and adults treated with
moderate-dose ICSs, there is some evidence sug-
gesting that the addition of LTRAs is associated
with improvements similar to those achieved by
doubling the ICS dose, but there is not yet suffi-
cient evidence to suggest equivalence of these
two therapeutic strategies.55
In adults, the addition of long-acting b2-
agonists added to 400 mg of chlorofluorocarbon-
propelled beclomethasone or its equivalent is more
effective than are LTRAs for lung function and for
reducing symptoms and the use of rescue b2-
agonists. However, both treatments had similar
rates of asthma exacerbations, and adverse events
were similar in both groups.56–58 No similar data
on children are yet available.
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Theophylline
In the few available studies that have evaluated add-
on therapy for patients on ICSs, theophylline was
less effective for improving asthma control than
were long-acting b2-agonists or LTRAs.59
Inhalation Devices
Inhalation devices were reviewed only for child-
hood asthma.
Recommendations
1. At each contact, health care professionals
should work with patients and their fam-
ilies on inhaler technique (level I).
2. When prescribing a pressurized metered-
dose inhaler (pMDI) for maintenance or
acute asthma, physicians should recom-
mend use of a valved spacer, with
mouthpiece when possible, for all children
(level II).
3. Although physicians should allow chil-
dren choice of inhaler device,
breath-actuated devices such as dry-powder
inhalers offer a simpler option for main-
tenance treatment for children above 5
years of age (level IV).
4. Children tend to “auto-scale” their inhaled
medication dose, and the same dose of
maintenance medication can be used at all
ages for all medications (level IV).
5. Physicians, educators, and families should
be aware that jet nebulizers are rarely indi-
cated for the treatment of chronic or acute
asthma (level I).
Reproduced with permission from the Canadian
Medical Association Journal.
The delivery of medicinal aerosols depends
on adequate inhalation technique. After repeated
instruction and demonstration, more than 
90% of children are able to achieve the correct
inhalation technique.60,61 Better knowledge of
asthma, increased satisfaction with education,
and diminished asthma instability and attacks 
are associated with improved inhalation 
technique.62,63
One of the more difficult inhalation tech-
niques is the use of a pressurized metered-dose
inhaler (pMDI).64,65 The use of a spacer with a
pMDI is strongly recommended for children. The
pMDI with a spacer can be used in place of the wet
nebulizer for children of all ages in both acute and
chronic care settings.66–71 The use of a mouth-
piece rather than a mask (generally with children
aged 4 or 5 years) maximizes lung deposition.72
By 5 to 6 years of age, children can generally
use dry-powder inhalers, such as the Turbuhaler
and the Diskus inhaler.73–75 Adults prefer breath-
actuated dry-powder inhalers to pMDIs and per-
form better with them.64 Using more than one
inhalation device may worsen one’s technique
with each device.76
In young children,the deposition of medication
in the lungs is about a tenth of the dose that would
be delivered in adults. Thus,the same dose of main-
tenance medication can be used at all ages because
it will be “auto-scaled” down in children.77,78
Immunotherapy
The literature on immunotherapy was reviewed
only for childhood asthma, and the current rec-
ommendations are directed toward the treatment
of children.
Recommendations
1. Physicians should only consider injection
immunotherapy using appropriate aller-
gens for the treatment of allergic asthma
when the allergic component is well doc-
umented (level I).
2. Physicians should not recommend the use
of injection immunotherapy in place of
avoidance of environmental allergens (level
III).
3. Physicians may consider injection
immunotherapy in addition to appropriate
environmental control and pharmacother-
apy when asthma control remains
inadequate (level IV).
 4. Immunotherapy is not recommended when
asthma is unstable (level III).
Reproduced with permission from the Canadian
Medical Association Journal.
Immunomodulation is the only currently avail-
able therapy aimed at modifying the underlying
disease process in asthma. Allergen immunother-
apy is defined by the World Health Organization
as therapeutic vaccination for allergic diseases.79
Although debate about the value of immunother-
apy continues, meta-analysis and review of
immunotherapy support its potential value in
childhood.80 Early immunotherapy may prevent
the development of asthma in children sensitized
to house dust mites.81 Allergen immunotherapy
should be combined with allergen avoidance,
pharmacotherapy, and patient education. Fur-
thermore, appropriate immunotherapy requires
the use of single well-defined allergens that reach
a final dose sufficient to ensure effectiveness.
The value of immunotherapy that uses multiple
allergens (as commonly undertaken) remains sus-
pect.
Education and Follow-Up
Recommendations
1. Education is an essential component of
asthma therapy and should be offered to
all patients; educational interventions may
be of particular benefit in patients with
high asthma-related morbidity or severe
asthma and at the time of emergency
department visits and hospital admission
(level I). Education programs should be
evaluated (level III).
2. All patients should monitor their asthma,
using symptoms or peak expiratory flow
(PEF) measurement (level I), and should
have written action plans for self-
management that include medication
adjustment in response to severity or fre-
quency of symptoms, the need for
symptom relief medication, or a change
in PEF (level I).
3. Asthma control criteria should be assessed
at each visit (level IV). Measurement of pul-
monary function,preferably by spirometry,
should be done regularly (level III) in adults
and in children 6 years of age and older.
4. Socioeconomic and cultural factors should
be taken into account in designing asthma
education programs (level II).
Reproduced with permission from the Canadian
Medical Association Journal.
Education about asthma is an important part
of asthma management and should aim primarily
at changing the patient’s behaviour rather than
simply improving the patient’s knowledge.82
Patients with marked asthma-related morbidity
and the need for frequent acute care should be 
targeted for asthma education. In this population,
structured education with a written self-
management plan, regular medical reassessment,
and a review of key educational concepts reduces
the number of emergency department visits.82–84
Recent studies, including meta-analyses in
children and adults, have confirmed that various
methods of asthma education can improve symp-
toms; improve the emotional state; improve com-
munication with family members, school, and
physicians; reduce school absenteeism; reduce
activity restriction; increase self-management
skills; reduce morbidity; improve lung function;
improve quality of life; reduce exacerbation rates;
and reduce the need for oral corticosteroids.85–97
Beneficial effects were observed in a study in
which education was provided to adolescents by
peers.93Long-term outcomes may be improved fur-
ther by reinforcement visits.91Internet-based edu-
cation may also improve adherence to the treatment
plan for children. Education improves adherence
to some environmental control measures (such as
dust mite reduction) but is less helpful for the
avoidance of animals by sensitized subjects.90
Conclusion
In Canadian children and adults with asthma, poor
control remains prevalent, resulting in preventable
morbidity, acute care visits, hospitalization, and
32 Allergy, Asthma, and Clinical Immunology / Volume 2, Number 1, Spring 2006
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even (fortunately rarely) death.98 In many cases,
poor asthma outcomes can be avoided by ensur-
ing that inhaled corticosteroids are started early and
used as regular long-term maintenance therapy,
with special care taken to ensure patient compli-
ance. Other crucial elements in achieving and
maintaining good asthma control (see Table 2)
are environmental control measures, asthma edu-
cation, treatment of comorbidity, and the appro-
priate use of add-on therapies.
It is hoped that these guidelines will improve
asthma control in the many Canadians who are cop-
ing with this far-too-common disease.
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